Introduction
Opioids have formed a mainstay of the analgesia ladder. They are commonly used in the anaesthesia setting in the treatment of post-operative pain but have widespread use in pain management and palliative care. Within the critical care setting often short acting opioids including codeine, oxycodone and morphine can be used as an infusion. Opiates have a wide range of side effects due to their narrow therapeutic window. Common side effects include nausea, vomiting, constipation, and drowsiness. More serious effects include opiate-induced respiratory distress and addiction. There is an urgent clinical need for safer opiates in analgesia. In this article we aim to address emerging opioids and their possible future use. Oliceridine is an opioid which has been approved by the Food and Drug Administration (FDA).
The concept of biased agonism and pharmaco-physiology of opioid receptors
Biased agonism is a term which describes a ligand selectively activating a receptor using one of several signalling pathways, largely within G-protein couple receptors (GPCR) (Gundry et al., 2017). The opioid receptor exists as four main types of receptors delta (δ), kappa (κ), mu (μ) and nociception receptor (Machelska et al., 2020). It is often the μ receptor which is the receptor of target in opioids treatment of analgesia. The activation of GPCR including opioid receptors leads to an activation of a signalling pathway. In the case of opioid receptors, the activation leads to downstream pathway of inhibition of adenylate cyclase and decrease in cyclic AMP leading to mitogen-activated protein kinase (MAPK) signalling via β arrestin (Connor & Christie 1999). Opioid activation of the opioid receptor leads to suppression of excitatory neurotransmitter release such as substance P, glutamate and calcitonin gene-related peptide. Oliceridine is described as an opioid analgesic which acts on the μ receptor (Ok et al 2018). Current literature also suggests that as oliceridine does not use the β arresting2 pathway thus not having harmful side effects of opioids (Gillis et al 2020). These side effects include nausea, vomiting, addiction, and tolerance. The mechanism of opioid agonist non-selectively activating G protein coupled receptor and β-arresting mediated signalling is explained in diagram 1.
Diagram-1 showing the stimulation of µ receptor by traditional opioids: both GPCRs and β-arrestin
pathways are recruited.
µ receptor